13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04391023 (ClinicalTrials.gov) | May 15, 2020 | 12/5/2020 | Cerebellar tDCS and Balance Training in PwMS | The Effects of 2 mA and 4 mA Cerebellar Transcranial Direct Current Stimulation and Balance Training to Reduce Fall Risk in People With Multiple Sclerosis | Multiple Sclerosis | Device: Sham Transcranial Direct Current Stimulation (tDCS);Behavioral: Balance Training;Device: 2 mA Transcranial Direct Current Stimulation;Device: 4 mA Transcranial Direct Current Stimulation | University of Iowa | NULL | Not yet recruiting | 18 Years | 70 Years | All | 30 | N/A | United States |